CD44 3'-UTR overexpression inhibits tumor proliferation, angiogenesis, and docetaxel resistance in breast cancer by serving as a competitor to the CDC42 3'-UTR for miR-216a, miR-330, and miR-608 binding 61. This evidence concerns the gene CD44 and breast cancer.